Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$0.968
−$0.0112 · -1.14%
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Previous close
$0.968
−$0.0112 · -1.14%
After-hours
$0.97
+$0.002 · +0.21%
Sep 4, 7:42 PM ET
Regular session · ET · Market data may be delayed.
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Day range
Current $0.968
52-week range
Current $0.968
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Sentiment
59
Mixed
Risk
69
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Day range
Current $0.968
52-week range
Current $0.968
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17K USD | — | — | 86K USD | — |
| Cost of goods sold | 844K USD | 16K USD | 15K USD | 15K USD | 7K USD |
| Gross profit | −827K USD | −16K USD | −15K USD | 71K USD | −7K USD |
| Research and development | 1.14M USD | 11.71M USD | 6.04M USD | 4.42M USD | 2.86M USD |
| Selling, general, and administrative | 3.02M USD | 2.95M USD | 3.55M USD | 4.45M USD | 4.35M USD |
| Operating expenses | 4.16M USD | 14.66M USD | 9.58M USD | 8.87M USD | 7.21M USD |
| Interest income | 120K USD | 101K USD | 406K USD | 160K USD | — |
| Interest expense | 10K USD | 14K USD | 384K USD | 61K USD | 10K USD |
| Depreciation and amortization | 774K USD | 16K USD | 15K USD | 15K USD | 7K USD |
| Operating income | −4.99M USD | −14.67M USD | −9.58M USD | −8.87M USD | −7.21M USD |
| Net income | −4.84M USD | −14.59M USD | −9.34M USD | −8.79M USD | −7.25M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 6, 2026 | 1:5 | — | — |
Stock split | Nov 21, 2024 | 1:4 | — | — |
Stock split | Sep 9, 2024 | 1:6 | — | — |
Stock split | Jul 3, 2023 | 1:10 | — | — |
Effective Feb 6, 2026
1:5
Effective Nov 21, 2024
1:4
Effective Sep 9, 2024
1:6
Effective Jul 3, 2023
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
